What is Roth Capital's Estimate for ChromaDex Q2 Earnings?

ChromaDex Co. (NASDAQ:CDXC - Free Report) - Equities research analysts at Roth Capital issued their Q2 2025 earnings estimates for shares of ChromaDex in a research note issued on Tuesday, November 5th. Roth Capital analyst S. Mcgowan forecasts that the company will post earnings of $0.01 per share for the quarter. The consensus estimate for ChromaDex's current full-year earnings is $0.02 per share. Roth Capital also issued estimates for ChromaDex's Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.03 EPS and FY2026 earnings at $0.14 EPS.

Other equities analysts also recently issued research reports about the stock. HC Wainwright increased their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Monday. Roth Mkm raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, StockNews.com lowered shares of ChromaDex from a "strong-buy" rating to a "buy" rating in a report on Friday.

ChromaDex Stock Down 4.0 %

Shares of NASDAQ:CDXC traded down $0.27 during trading on Friday, hitting $6.50. The stock had a trading volume of 977,782 shares, compared to its average volume of 510,949. ChromaDex has a 12-month low of $1.32 and a 12-month high of $7.08. The stock has a market capitalization of $496.47 million, a price-to-earnings ratio of 650.65 and a beta of 1.88. The stock has a 50-day simple moving average of $3.83 and a two-hundred day simple moving average of $3.33.

ChromaDex (NASDAQ:CDXC - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The firm had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same period in the previous year, the company earned ($0.01) earnings per share.

Hedge Funds Weigh In On ChromaDex

A number of hedge funds have recently bought and sold shares of CDXC. SG Americas Securities LLC purchased a new stake in shares of ChromaDex in the first quarter valued at approximately $54,000. Acadian Asset Management LLC acquired a new position in ChromaDex during the first quarter worth $67,000. Lazard Asset Management LLC purchased a new position in ChromaDex during the first quarter valued at $43,000. Perritt Capital Management Inc. acquired a new stake in shares of ChromaDex in the first quarter valued at about $139,000. Finally, Miracle Mile Advisors LLC purchased a new stake in shares of ChromaDex during the second quarter worth about $27,000. Hedge funds and other institutional investors own 15.41% of the company's stock.

Insiders Place Their Bets

In related news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 9.64% of the company's stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.